[Treatment of acute myelogenous leukemia in patients more than 80 years old]. 1997

H Takeyama, and Y Yamamoto, and Y Miyata, and H Yamada, and E Watanabe, and H Aoki, and M Iinuma
Dept. of Internal Medicine, Nagoya Ekisaikai Hospital.

We studied fifteen patients older than 80 years of age with acute myelogenous leukemia (AML) treated between 1984 and 1996. Among 15 cases of AML including 7 de novo cases and 8 from myelodysplastic syndrome (MDS) or hypoplastic leukemia, 14 patients had complications, including cardiovascular disease, diabetes mellitus or other malignancies. Although patients with de novo AML showed high peripheral WBC counts and higher cellularity of bone marrow than those from MDS or hypoplastic leukemia, it was difficult in some cases to distinguish these types of AML from hematological findings. Of the 6 AML cases, three had entered complete remission (CR) by a standard dose of combination chemotherapy (BHAC-DMP). One CR patient has had CR for more than 9 years now with good QOL. Among the 3 patients treated by low-dose Ara-C, one attained CR but only for a short period. Four other patients received BRM, such as G-CSF or Ubenimex, and 2 patients died without chemotherapy. Since AML at more than 80 years of age is a highly heterogenous disease, it would be reasonable to give antileukemic agents according to the individual patient's condition.

UI MeSH Term Description Entries
D008297 Male Males
D011239 Prednisolone A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. Di-Adreson-F,Predate,Predonine,Di Adreson F,DiAdresonF
D011788 Quality of Life A generic concept reflecting concern with the modification and enhancement of life attributes, e.g., physical, political, moral, social environment as well as health and disease. HRQOL,Health-Related Quality Of Life,Life Quality,Health Related Quality Of Life
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D003630 Daunorubicin A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS. Daunomycin,Rubidomycin,Rubomycin,Cerubidine,Dauno-Rubidomycine,Daunoblastin,Daunoblastine,Daunorubicin Hydrochloride,NSC-82151,Dauno Rubidomycine,Hydrochloride, Daunorubicin,NSC 82151,NSC82151
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old

Related Publications

H Takeyama, and Y Yamamoto, and Y Miyata, and H Yamada, and E Watanabe, and H Aoki, and M Iinuma
November 1985, The Journal of urology,
H Takeyama, and Y Yamamoto, and Y Miyata, and H Yamada, and E Watanabe, and H Aoki, and M Iinuma
December 2002, American journal of hematology,
H Takeyama, and Y Yamamoto, and Y Miyata, and H Yamada, and E Watanabe, and H Aoki, and M Iinuma
December 1989, Nihon Ketsueki Gakkai zasshi : journal of Japan Haematological Society,
H Takeyama, and Y Yamamoto, and Y Miyata, and H Yamada, and E Watanabe, and H Aoki, and M Iinuma
January 1982, Acta haematologica,
H Takeyama, and Y Yamamoto, and Y Miyata, and H Yamada, and E Watanabe, and H Aoki, and M Iinuma
October 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
H Takeyama, and Y Yamamoto, and Y Miyata, and H Yamada, and E Watanabe, and H Aoki, and M Iinuma
June 1986, Surgery, gynecology & obstetrics,
H Takeyama, and Y Yamamoto, and Y Miyata, and H Yamada, and E Watanabe, and H Aoki, and M Iinuma
January 1974, Annals of internal medicine,
H Takeyama, and Y Yamamoto, and Y Miyata, and H Yamada, and E Watanabe, and H Aoki, and M Iinuma
April 2013, Oncology letters,
H Takeyama, and Y Yamamoto, and Y Miyata, and H Yamada, and E Watanabe, and H Aoki, and M Iinuma
August 1964, American journal of clinical pathology,
H Takeyama, and Y Yamamoto, and Y Miyata, and H Yamada, and E Watanabe, and H Aoki, and M Iinuma
June 1991, The American journal of gastroenterology,
Copied contents to your clipboard!